WO2021011885A1 - Claudin18 antibodies and methods of treating cancer - Google Patents

Descripción

International application published with international search report

WO2021088927A1 - Antibody-drug conjugates targeting claudin 18.2 - Google Patents

WO2021025177A1 - Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer - Google Patents

US5624821A - Antibodies with altered effector functions - Google Patents

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types - Einsele - 2020 - Cancer - Wiley Online Library

Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy, Biomarker Research

WO2021024020A1 - Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer - Google Patents

WO2022063272A1 - Novel anti-claudin18 antibodies - Google Patents

WO2021024020A1 - Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer - Google Patents

Emerging new therapeutic antibody derivatives for cancer treatment

Sugerir búsquedas

Frontiers Effects of Age-of-Acquisition on Proficiency in Polish Sign Language: Insights to the Critical Period Hypothesis

The 2024 Guide to 90% VA Disability Benefits - Hill & Ponton, P.A.

Synthesis and Preliminary In Vitro and In Vivo Evaluation of Thiirane‐Based Slow‐Binding MMP Inhibitors as Potential Radiotracers for PET Imaging - Hohn - 2018 - ChemistrySelect - Wiley Online Library

Thanet is CCTV capital of Kent, while Maidstone traders concerned over lack of cameras